Leerink Partners Believes AbbVie (NYSE: ABBV) Still Has Room to Grow

In a report issued on July 26, Geoff Porges from Leerink Partners maintained a Buy rating on AbbVie (ABBVResearch Report). The company’s shares closed last Tuesday at $117.96, close to its 52-week high of $118.67.

According to TipRanks.com, Porges is a 3-star analyst with an average return of 3.4% and a 47.8% success rate. Porges covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Theravance Biopharma, and Assembly Biosciences.

AbbVie has an analyst consensus of Strong Buy, with a price target consensus of $123.50, which is a 4.8% upside from current levels. In a report issued on July 26, Truist Financial also initiated coverage with a Buy rating on the stock with a $118.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $118.67 and a one-year low of $79.11. Currently, AbbVie has an average volume of 6.1M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.